AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
184.08
-2.50 (-1.34%)
Nov 3, 2026, 12:23 PM EST - Market open
AstraZeneca Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 62,384 | 58,739 | 54,073 | 45,811 | 44,351 | 37,417 |
Revenue Growth | 7.32% | 8.63% | 18.04% | 3.29% | 18.53% | 40.58% |
Gross Profit Gross Profit Growth | 51,019 | 47,993 | 44,435 | 37,766 | 35,710 | 25,412 |
Operating Income Operating Income Growth | 16,097 | 14,292 | 12,929 | 9,699 | 8,812 | 2,897 |
Net Income Net Income Growth | 11,030 | 10,225 | 7,035 | 5,955 | 3,288 | 112 |
Earnings Per Share EPS Growth | 7.06 | 6.54 | 4.50 | 3.81 | 2.11 | 0.08 |
EPS Growth | 17.30% | 45.33% | 18.11% | 80.57% | 2571.43% | -96.76% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Oncology Oncology Growth | 28,915 | 25,618 | 20,275 | 17,145 | 14,631 | 12,940 |
BioPharmaceuticals: Cardiovascular, Renal & Metabolism PR (CVRM) BioPharmaceuticals: Cardiovascular, Renal & Metabolism PR (CVRM) Growth | 11,662 | 12,774 | 12,448 | 10,585 | 9,188 | 8,088 |
BioPharmaceuticals: Respiratory & Immunology PR (R&I) BioPharmaceuticals: Respiratory & Immunology PR (R&I) Growth | 9,640 | 8,866 | 7,416 | 6,107 | 5,765 | 6,034 |
BioPharmaceuticals Infectious Disease PR (ID) BioPharmaceuticals Infectious Disease PR (ID) Growth | 1,178 | 1,268 | 1,058 | 1,012 | 4,736 | 4,665 |
Rare Disease Rare Disease Growth | 9,917 | 9,126 | 8,668 | 7,764 | 7,053 | 3,110 |
Other Medicines Other Medicines Growth | 953 | 988 | 1,073 | 1,176 | 1,625 | 1,704 |
Collaboration Collaboration Growth | 119 | 99 | 3,135 | 2,022 | 1,353 | 876 |
Revenue (Total) Revenue (Total) Growth | 62,384 | 58,739 | 54,073 | 45,811 | 44,351 | 37,417 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 8,166 | 5,719 | 5,525 | 5,860 | 6,244 | 6,398 |
Total Debt Total Debt Growth | 34,325 | 29,703 | 30,460 | 29,649 | 31,135 | 33,363 |
Net Cash (Debt) Net Cash Growth | -26,159 | -23,984 | -24,935 | -23,789 | -24,891 | -26,965 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -16.75 | -15.35 | -15.95 | -15.23 | -15.96 | -18.90 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 13,232 | 14,575 | 11,861 | 10,345 | 9,808 | 5,963 |
Capital Expenditures CapEx Growth | -3,022 | -2,810 | -1,924 | -1,361 | -1,091 | -1,091 |
Free Cash Flow Free Cash Flow Growth | 10,210 | 11,765 | 9,937 | 8,984 | 8,717 | 4,872 |
Free Cash Flow Growth | -19.34% | 18.40% | 10.61% | 3.06% | 78.92% | 26.94% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 81.78% | 81.71% | 82.18% | 82.44% | 80.52% | 67.92% |
Operating Margin | 25.80% | 24.33% | 23.91% | 21.17% | 19.87% | 7.74% |
Pretax Margin | 21.32% | 21.11% | 16.07% | 15.06% | 5.64% | -0.71% |
Profit Margin | 17.68% | 17.41% | 13.01% | 13.00% | 7.41% | 0.30% |
FCF Margin | 16.37% | 20.03% | 18.38% | 19.61% | 19.66% | 13.02% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 3.230 | 3.200 | 3.100 | 2.900 | 2.900 | 2.870 |
Dividend Per Share Growth | 3.19% | 3.23% | 6.90% | 0% | 1.04% | 2.50% |
Dividend Yield | 1.75% | 1.72% | 2.37% | 2.15% | 2.15% | 2.44% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 25.81 | 28.15 | 28.88 | 35.14 | 63.70 | 1625.31 |
P/FCF Ratio | 28.25 | 24.46 | 20.45 | 23.29 | 24.03 | 37.36 |
PS Ratio | 4.62 | 4.90 | 3.76 | 4.57 | 4.72 | 4.87 |